Molecular Characterization of the Dopamine Transporter
Overview
Affiliations
Neurotransmission, which represents chemical signalling between neurons, usually takes place at highly differentiated anatomical structures called synapses. To fulfill both the time and space confinements required for optimal neurotransmission, highly specialized proteins, known as transporters or uptake sites, occur and operate at the presynaptic plasma membrane. Using the energy provided by the Na+ gradient generated by the Na+/K(+)-transporting ATPase, these transporters reuptake the neurotransmitters soon after their release, thereby regulating their effective concentrations at the synaptic cleft and the availability of neurotransmitters for a time-dependent activation of both pre- and postsynaptic receptors. The key role these proteins play in normal neurotransmission is further emphasized when the physiological and social consequences of drugs that interfere with the function of these transporters, such as the psychostimulants (e.g. amphetamine and cocaine) or the widely prescribed antidepressant drugs, are considered. In this review, Bruno Giros and Marc Caron elaborate on the potential consequences of the recent molecular cloning of the dopamine and related transporters and summarize some of the interesting properties that are emerging from this growing family of Na(+)- and Cl(-)-dependent transporters.
Evidence of COMT dysfunction in the olfactory bulb in Parkinson's disease.
Beauchamp L, Ellett L, Juan S, Liu X, Hunt C, Parish C Acta Neuropathol. 2025; 149(1):21.
PMID: 40024917 PMC: 11872990. DOI: 10.1007/s00401-025-02861-y.
generation of dual-target compounds using artificial intelligence.
Yasuda K, Berenger F, Amaike K, Ueda A, Nakagomi T, Hamasaki G iScience. 2025; 28(1):111526.
PMID: 39801837 PMC: 11721219. DOI: 10.1016/j.isci.2024.111526.
Bolden N, Pavchinskiy R, Melikian H J Neurochem. 2024; 169(1):e16284.
PMID: 39655745 PMC: 11631176. DOI: 10.1111/jnc.16284.
Oligomerization of Monoamine Transporters.
Paul A, Shukla D Subcell Biochem. 2024; 104:119-137.
PMID: 38963486 DOI: 10.1007/978-3-031-58843-3_7.
Predicting therapeutic and side effects from drug binding affinities to human proteome structures.
Sawada R, Sakajiri Y, Shibata T, Yamanishi Y iScience. 2024; 27(6):110032.
PMID: 38868195 PMC: 11167438. DOI: 10.1016/j.isci.2024.110032.